Veru Inc. (NASDAQ:VERU) Shares Acquired by Choreo LLC

Choreo LLC increased its holdings in shares of Veru Inc. (NASDAQ:VERU) by 261.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 332,050 shares of the company’s stock after acquiring an additional 240,134 shares during the quarter. Choreo LLC owned about 0.23% of Veru worth $292,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Cetera Advisors LLC acquired a new position in shares of Veru during the 1st quarter worth approximately $33,000. Rhumbline Advisers boosted its stake in Veru by 3,994.8% during the second quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock worth $96,000 after buying an additional 110,857 shares during the last quarter. SeaCrest Wealth Management LLC boosted its stake in Veru by 313.8% during the second quarter. SeaCrest Wealth Management LLC now owns 120,000 shares of the company’s stock worth $101,000 after buying an additional 91,000 shares during the last quarter. 180 Wealth Advisors LLC purchased a new stake in Veru in the 1st quarter valued at $120,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Veru in the 4th quarter worth $360,000. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Veru Trading Down 3.6 %

Shares of VERU stock opened at $0.78 on Wednesday. Veru Inc. has a twelve month low of $0.36 and a twelve month high of $1.92. The company’s 50-day moving average price is $0.87 and its 200-day moving average price is $0.97. The stock has a market cap of $114.63 million, a price-to-earnings ratio of -2.30 and a beta of -0.48.

Veru (NASDAQ:VERU) last posted its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The firm had revenue of $3.95 million during the quarter, compared to analyst estimates of $3.50 million. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. As a group, equities research analysts predict that Veru Inc. will post -0.3 EPS for the current year.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.